BioAtla, Inc.
General ticker "BCAB" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $29.6M (TTM average)
BioAtla, Inc. follows the US Stock Market performance with the rate: 33.9%.
Estimated limits based on current volatility of 8.0%: low 0.27$, high 0.32$
Factors to consider:
- Total employees count: 65 (-1.5%) as of 2023
- Top business risk factors: Limited operating history, Insufficient funding, Regulatory and compliance, Labor/talent shortage/retention, Geopolitical risks
- Current price 64.5% below estimated low
- Earnings for 9 months up through Q3 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [0.68$, 2.27$]
- 2025-12-31 to 2026-12-31 estimated range: [0.76$, 2.40$]
Financial Metrics affecting the BCAB estimates:
- Positive: with PPE of -0.5 at the end of fiscal year the price was neutral
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -197.37 <= 0
- Positive: Investing cash flow per share per price, % of 0 > -0.63
- Positive: 19.41 < Shareholder equity ratio, % of 27.21 <= 42.77
- Positive: Interest expense per share per price, % of 0 <= 0.01
- Positive: Inventory ratio change, % of 0 <= 0
Short-term BCAB quotes
Long-term BCAB plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $0.00MM | $11.00MM |
| Operating Expenses | $108.14MM | $129.69MM | $84.94MM |
| Operating Income | $-108.14MM | $-129.69MM | $-73.94MM |
| Non-Operating Income | $1.66MM | $6.22MM | $4.17MM |
| R&D Expense | $79.35MM | $103.73MM | $63.09MM |
| Income(Loss) | $-106.48MM | $-123.46MM | $-69.78MM |
| Profit(Loss)* | $-105.28MM | $-123.46MM | $-69.78MM |
| Stockholders Equity | $180.34MM | $70.67MM | $14.27MM |
| Assets | $225.74MM | $119.66MM | $52.42MM |
| Operating Cash Flow | $-90.42MM | $-104.02MM | $-71.94MM |
| Capital expenditure | $0.27MM | $0.10MM | $0.00MM |
| Investing Cash Flow | $-0.27MM | $-0.10MM | $0.00MM |
| Financing Cash Flow | $61.21MM | $0.08MM | $9.51MM |
| Earnings Per Share** | $-2.70 | $-2.58 | $-1.44 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.